FRE.AU – Firebrick Pharma Ltd

Last Day

Drug Manufacturers – General

• Trailing PE:
• Forward PE:
• Price Sales TTM:
• Price Book MRQ:
• Enterprise Value:
• Enterprise Value Revenue:
• Enterprise Value Ebitda:
• Beta:

• Shares Outstanding:
• Market Capitalization:
• Market Capitalization Mln:
• EBITDA:
• PE Ratio:
• PEG Ratio:
• Wall Street Target Price:
• Book Value:
• Dividend Share:
• Dividend Yield:
• Earnings Share:
• EPS Estimate Current Year:
• EPS Estimate Next Year:
• EPS Estimate Next Quarter:
• EPS Estimate Current Quarter:
• Most Recent Quarter:
• Profit Margin:
• Operating Margin TTM:
• Return On Assets TTM:
• Return On Equity TTM:
• Revenue TTM:
• Revenue Per Share TTM:
• Quarterly Revenue Growth YOY:
• Gross Profit TTM:
• Diluted Eps TTM:
• Quarterly Earnings Growth YOY:

• Type:
• Name:
• Exchange:
• Currency Code:
• Currency Name:
• Currency Symbol:
• Country Name:
• Fiscal Year End:
• IPO Date:
• International Domestic:
• Sector:
• Industry:
• Address:
• Country:
• Listings:
• Web URL:
• Full Time Employees:
• Updated At:
• Gic Sector:
• Gic Group:
• Gic Industry:
• Gic SubIndustry:

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia. Address: 440 Collins Street, Melbourne, VIC, Australia, 3000

The data, information and layout displayed above cannot be used for commercial purpose. We do not accept any liability for reliance of the information above. We can provide detailed description of source data regarding our industry research and valuation research to our clients upon request.